Literature DB >> 21241760

RNA interference therapy via functionalized scaffolds.

Michael Monaghan1, Abhay Pandit.   

Abstract

Tissue engineering aims to provide structural and biomolecular cues to compromised tissues through scaffolds. An emerging biomolecular cue is that of RNA interference by which the expression of genes can be silenced through a potent endogenous pathway. Recombinant viral-based approaches in RNAi delivery exist; however non-viral strategies offer many opportunities to exploit this mechanism of regulation in a safer way. Current RNAi therapies in clinical trials are without a vector (naked) or have slightly modified structures. Modification of these molecules with efficient backbone moieties for improved stability and potency, protecting and buffering them with delivery vehicles, and using scaffolds as reservoirs of delivery is at the frontier of current research. However, to enable an efficient sustained therapeutic effect scaffolds have a potentially significant role to play. This review presents non-viral delivery of RNAi that have been attempted via tissue engineered scaffolds. For RNAi to have a clinical impact, it is imperative to evaluate optimal delivery systems to ensure that the efficacy of this promising technology can be maximized.
Copyright © 2011 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2011        PMID: 21241760     DOI: 10.1016/j.addr.2011.01.006

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  26 in total

1.  RNAi functionalized scaffold for scarless skin regeneration.

Authors:  Xing Liu; Lie Ma; Changyou Gao
Journal:  Organogenesis       Date:  2013-04-01       Impact factor: 2.500

2.  Characterization and evaluation of a peptide-based siRNA delivery system in vitro.

Authors:  Baoling Chen; Kimoon Yoo; Wen Xu; Ran Pan; Xiao Xia Han; P Chen
Journal:  Drug Deliv Transl Res       Date:  2017-08       Impact factor: 4.617

Review 3.  Current Transport Systems and Clinical Applications for Small Interfering RNA (siRNA) Drugs.

Authors:  Fang Liu; Chunfang Wang; Yuantao Gao; Xiao Li; Feng Tian; Yongtao Zhang; Mingyang Fu; Pengfei Li; Yali Wang; Fei Wang
Journal:  Mol Diagn Ther       Date:  2018-10       Impact factor: 4.074

Review 4.  MicroRNAs in cancer: glioblastoma and glioblastoma cancer stem cells.

Authors:  Jeffrey V Brower; Paul A Clark; Will Lyon; John S Kuo
Journal:  Neurochem Int       Date:  2014-06-14       Impact factor: 3.921

5.  An antibody fragment functionalized dendritic PEGylated poly(2-(dimethylamino)ethyl diacrylate) as a vehicle of exogenous microRNA.

Authors:  M Monaghan; U Greiser; H Cao; W Wang; A Pandit
Journal:  Drug Deliv Transl Res       Date:  2012-10       Impact factor: 4.617

6.  Down-regulation of Noggin and miR-138 coordinately promote osteogenesis of mesenchymal stem cells.

Authors:  Xing-Kun Sun; Jin Zhou; Lei Zhang; Tian Ma; Yu-Han Wang; Yan-Mei Yang; Yan-Ting Tang; Hong Li; Li-Jun Wang
Journal:  J Mol Histol       Date:  2017-11-02       Impact factor: 2.611

7.  Photocrosslinkable, biodegradable hydrogels with controlled cell adhesivity for prolonged siRNA delivery to hMSCs to enhance their osteogenic differentiation.

Authors:  Minh Khanh Nguyen; Alexandra McMillan; Cong Truc Huynh; Daniel S Schapira; Eben Alsberg
Journal:  J Mater Chem B       Date:  2016-12-14       Impact factor: 6.331

Review 8.  MicroRNA delivery for regenerative medicine.

Authors:  Bo Peng; Yongming Chen; Kam W Leong
Journal:  Adv Drug Deliv Rev       Date:  2015-05-27       Impact factor: 15.470

9.  Effects of CD25siRNA gene transfer on high-risk rat corneal graft rejection.

Authors:  Qin Qin; Yunjie Shi; Qingqing Zhao; Dan Luo; Yuan Chen; Jing Wu; Min Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-31       Impact factor: 3.117

10.  Functionalized, biodegradable hydrogels for control over sustained and localized siRNA delivery to incorporated and surrounding cells.

Authors:  Khanh Nguyen; Phuong Ngoc Dang; Eben Alsberg
Journal:  Acta Biomater       Date:  2012-08-16       Impact factor: 8.947

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.